New Drug Baxdrostat Shows Promise in Lowering Blood Pressure and Protecting Kidneys in Clinical Trial
A new experimental drug, baxdrostat, has demonstrated significant potential in lowering blood pressure and reducing kidney damage in patients with chronic kidney disease and uncontrolled hypertension. In a Phase 2 clinical trial, the drug was added to standard treatment and resulted in a greater reduction in systolic blood pressure compared to a placebo. Additionally, it significantly decreased a urine marker associated with kidney and cardiovascular risk. Baxdrostat works by inhibiting the production of aldosterone, a hormone that can contribute to high blood pressure and kidney damage. The trial involved 195 participants with chronic kidney disease and high blood pressure, who were already on standard medications. The results showed that baxdrostat not only lowered blood pressure but also reduced urine albumin levels, indicating potential kidney protection. 
